Professor of Respiratory Medicine, CHU Grenoble-Alpes. Honorary president IFCT Intergroupe Francophone de Cancérologie Thoracique. My opinions are my own.
France
Joined March 2013
- Tweets5.2K
- Following370
- Followers1.3K
- Likes2.5K
denis Moro-Sibilot retweeted
1/2
🫁🫁 EGFRm+ LUADs to SCLC transformation 🫁🫁
💥💥Osimertinib + Platinum + Etoposide
💥💥EGFR / TP53 / RB-1 mutant lung cancer
💥💥Translational research
#Lungcancer
#egfr
#SCLC
@ScienceMagazine
@ScienceTM
denis Moro-Sibilot retweeted
Can you prevent small cell transformation in high risk EGFR mutant NSCLC with osimertinib + platinum/etoposide? No. Prospective trial with high response rate, but also high rate of transformation.
By Helena Yu and MSK colleagues
published in @ScienceTM science.org/doi/10.1126/scit…
denis Moro-Sibilot retweeted
🚨 Another HER3 ADC delivers in EGFR-mutant lung cancer!
Published in @TheLancet, the phase III HERON-Lung01 trial evaluated ruzaltatug rezetecan vs platinum-pemetrexed after EGFR-TKI progression.
🔬 498 patients | Key results:
📊 Median PFS: 8.3 vs 5.4 months
🔥 HR 0.47, a 53% reduction in progression/death hazard
⚠️ Grade ≥3 TRAEs: 41% vs 39%
My take: Another positive phase III ADC trial in EGFR-mutant NSCLC. Promising efficacy, but immature follow-up, pending OS data and an all-China population warrant caution.
The post-TKI treatment landscape is getting crowded!
@oncoalert #LungCancer #NSCLC #ADC
Full paper link in comment below ⬇️
denis Moro-Sibilot retweeted
Dalmelitinib Plus Aumolertinib in Advanced #NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.
Read the full article. bit.ly/3UqqJLh
#LungCancer
denis Moro-Sibilot retweeted
Always enjoy discussing the latest data with @high5md - this session on the biggest impact data from #ESMO26, gaining perspectives from Drs. @Griesinger35711 @Alfdoc2 @HendriksLizza @nicogirardcurie @DMSLung @DrRiyazShah @MartinReck2
high5oncology.tv/meeting-cov…
denis Moro-Sibilot retweeted
IFCT ONCOBRAF study 🇫🇷 #ESMO26, Encorafenib + Binimetinib shows comparable performance 1L & 2L (mPFS: 11.1 & 9.2 mo) in #BRAF V600mut NSCLC pts, with prolonged survival of 41.1 (1L) and 37.5 mo (2L) confirming this combo as a standard. Come by to learn more and chat @C_Ricordel
denis Moro-Sibilot retweeted
🆙#ESMO26 Rapid Oral II: #LCSM Mets
🔥IFCT-2103 DIAL: Analysis of the Phase 2 Part of a Phase 2-3 Randomized Trial, Comparing Continuation Pembrolizumab (± Pemetrexed) up to 2 Years Versus Observation (± Pemetrexed), in Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC) With Disease Control (DC) at 6 Months
🎙️Dr. Anne-Claire Toffart
🔢2618RO
🎯Similar 18-Mo OS With De-escalation (Observation) vs Continuation: 88.1% vs 83.3% (n=84)
🎯Lower irAEs With De-escalation (47.8% vs 85.1%)
🎯Phase 3 Accrual Ongoing
☑️NCT05255302
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
🆙#ESMO26 Rapid Oral II: #LCSM Mets
🔥IFCT-2103 DIAL: Analysis of the Phase 2 Part of a Phase 2-3 Randomized Trial, Comparing Continuation Pembrolizumab (± Pemetrexed) up to 2 Years Versus Observation (± Pemetrexed), in Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC) With Disease Control (DC) at 6 Months
🎙️Dr. Anne-Claire Toffart
🔢2618RO
🎯Similar 18-Mo OS With De-escalation (Observation) vs Continuation: 88.1% vs 83.3% (n=84)
🎯Lower irAEs With De-escalation (47.8% vs 85.1%)
🎯Phase 3 Accrual Ongoing
☑️NCT05255302
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
denis Moro-Sibilot retweeted
A great presentation by Prof. Anne-Claire Toffart (Grenoble University Hospital), on behalf of the French Intergroup IFCT.
A very encouraging message, since longer is not systematically better! Accrual is continuing : Join the French investigator centers already engaged 🫁
denis Moro-Sibilot retweeted
PARSEE trial- while we might be parseeing the data for a while, on surface they seem per se immediately practice-changing!
Chemo/IO led to impressive benefits for tps score>50 pts over pembro alone when it comes to primary endpoint of PFS, trends for OS, dramatic reduction in early progression (25 to 5% or so) - at cost of anticipated toxicities
Benefit surprisingly just as much in tps >90! Only subset of note w limited benefits - pts>70 yrs
So it seems chemo/IO is now the best SOC for pts w non-AGA tps>50 advanced NSCLC w IO likely most appropriate for frail elderly
Special kudos to Dr. Decroisette and the French GFPC study team for completing such an important trial! Merci!
#lcsm
#ESMO26
denis Moro-Sibilot retweeted
#ESMO26 Presidential 1 :
#SCLC DeLLphi-305:
Who would have imagined some years ago that median OS of SCLC would equal that of non-AGA NSCLC!
#Tarlatamab as 1L maintenance with Durvalumab after induction chemoIO in ES-SCLC improved OS from 12.7 to an impressive 21.1m, corresponding to a HR of 0.42.
80% of patients alive and 38% progression-free at 12 months
The dawn of a new era for thoracic oncology and for the lives of our patients 💫✨
@myESMO @SclcSMASHERS
#ESMOAmbassadors
denis Moro-Sibilot retweeted
Off the rousing #ESMO26 oral presentation from Dr. @decroisette, the phase III PERSEE trial with simultaneous publication @Annals_Oncology. Combination of chemotherapy + pembrolizumab superior to pembro in PDL1 high NSCLC: PFS 16.1 vs 6.9m, HR 0.56!
annalsofoncology.org/article…
denis Moro-Sibilot retweeted
⏰ Less is better: 6 months chemo-immunotherapy compare to 2 years lead to similar survival and fewer side effects in patients with 1L stage IV, NSCLC, ICFT-2103 DIAL trial suggests. 🇫🇷 Congratulations for this academic effort !!
However, just informative or definitive evidence? What do you think! #ESMO26 #LCSM
denis Moro-Sibilot retweeted
🚨 医学界刚刚扔下一枚核弹：科学家找到了“一键清洗”大脑毒素的物理开关！
只需 10 分钟。不吃药，不动刀。阿尔茨海默病的毒性斑块直接被“冲刷”干净。
你的大脑里有一个专属的废物清理网络（类淋巴系统），负责清扫有毒蛋白和死细胞。
但它极其苛刻：只有在深度睡眠（慢波睡眠）时才会启动。
如果你长期熬夜、睡眠不足，垃圾就会在脑子里发臭、堆积，最终演变成不可逆的认知衰退和阿尔茨海默病。
直到今天，这个死局被打破了。
《Science Advances》最新发表的研究证实：科学家现在可以手动触发这个“深度清洁”程序，完全不需要你睡着。
他们使用 40.68 MHz 的超短波（USW），以非侵入式的方法照射大脑。
短短 10 分钟内，大脑的液体流动开始狂飙。
这些超短波强行将神经元同步到 Delta 状态——这正是深度睡眠时的脑波频率。大脑被瞬间“欺骗”，水通道全开，如同开启了高压水枪，疯狂清洗毒素。
在患有创伤性脑损伤和阿尔茨海默病的小鼠身上，测试结果极其震撼：
🧠 脑水肿迅速消退
🧹 有毒蛋白质被大量清除
📈 认知缺陷实质性逆转
没有开颅手术。没有昂贵的化学药物干预。
仅仅依靠一个特定的物理频率。
人类对抗脑部绝症和衰老的武器库里，多了一把降维打击的重狙。
Readers added context they thought people might want to know
该帖子对Science Advances研究存在夸大渲染。该研究仅在小鼠TBI和阿尔茨海默病模型中显示40.68 MHz超短波可增强类淋巴清除并改善部分症状，尚无人类临床试验数据支持其疗效或“一键清洗”作用。
science.org/doi/10.1126/sc…
denis Moro-Sibilot retweeted
In Beamion LUNG-1 with zongertinib, 8 paired tissue results from pts with PD showed two acquired HER2 mutations: T862A and S783C. Notably absent were T798I (gatekeeper) and C805S (binding site). The acquired mutations not detected in plasma. #WCLC26 @dplanchard
denis Moro-Sibilot retweeted
Early insights into resistance to HER2 TKIs in NSCLC emerged at #WCLC26. Zongertinib & sevabertinib now both approved as 1L+ treatment for advanced NSCLC with a HER2 TKD mt. While efficacy similar, these are distinct agents and we need to learn how to leverage those differences.
denis Moro-Sibilot retweeted
An unfortunate development in a SCLC landscape where post-tarlatamab, few approved options. Would not read too much into the withdrawal - need to wait for phase III results as phase II likely inadequate. The B7-H3 class holds great promise with tam-peli, ris-rez, & I-DXd.
Quite a surprise, I-dxd BLA application withdrawn. The wait for an ADC for small cell lung cancer outside China will continue, disappointing news #lcsm stocktitan.net/news/MRK/ifin…
denis Moro-Sibilot retweeted
Upcoming FDA approval decisions in Q4 2026
nature.com/articles/d41573-0…
Notable potential approvals include a first-in-class B7H3-targeted ADC for small-cell lung cancer, an ASO for chronic hepatitis B infection and a PD1 x VEGF bispecific antibody for non-small-cell lung cancer
denis Moro-Sibilot retweeted
Another step forward in targeting RAS.
A new @NatureMedicine phase 1 study of GFH375/VS-7375, an oral drug designed specifically for KRAS G12D, showed tumor shrinkage in about 1 in 3 heavily pretreated patients with pancreatic or lung cancer.
In pancreatic cancer, median PFS was 5.5 months and median OS 9.9 months. About a third of patients had grade ≥3 treatment-related side effects.
While the recently approved daraxonrasib targets multiple RAS mutations, this drug is selective for KRAS G12D. Still early, but another encouraging approach against a historically difficult target.
denis Moro-Sibilot retweeted
Dr. @alexdrilon at #WCLC26 presents 1L cohort of ARROS-1 trial of zidesamtinib in pts with ROS1 NSCLC. What a waterfall plot. RR 94% with 15% CR. mPFS not reached, PFS at 6m was 96% and at 12m was 90%. Intracranial RR 100%. In 78 pts who did not have brain metastases at baseline, no CNS events occurred to date. These are fantastic outcomes.
